Chiara Corpetti

Huntington’s disease may be facing a turning point with AMT-130. At 36 months, the gene therapy showed a 75% slowing in clinical progression. Positive trends also seen in cognitive and motor function: - Cognitive-SDMT 88% - Cognitive-SWRT 113% - Motor-TMS 59%

Breaking News: President Trump ordered U.S. agencies to loosen restrictions on psychedelic drugs, in a move aimed at accelerating research. nyti.ms/4tZeVvS

👀 Among our most-read in 2025: A major meta-analysis investigating the effects of antidepressants on cardiometabolic and other physiological parameters. Find out more: hubs.ly/Q03YQ-Y30

7/ FL-100 brings neuromodulation into the home. Could this be the start of a new wave of non-pharma, self-administered treatments in psychiatry?

6/ Safety profile? 🟢 Mild and manageable AEs: skin redness, irritation, transient concentration issues. But: the trial had limitations: – Blinding challenges – Interindividual variability in current flow – Restricted study population

🧵1/ The @US_FDA just approved FL-100, the first wearable at-home brain stimulation device for major depression. Developed by @flowneurosci, this marks a shift in how we think about non-pharma treatment options. 👇

7/ 🎯 This study adds clinical weight to the gut–brain axis in ageing. We’re only scratching the surface of what the microbiome and the gut-brain axis connection can do. Will future cognitive care include daily probiotics?

6/ Limits: ⚠️ No direct inflammatory biomarkers ⚠️ Mood data were self-reported ⚠️ 12-week duration limits conclusions on long-term impact Clinical trials are still in early evidence.

🧵1/ Can probiotics enhance brain health in healthy older adults? A 12-week RCT tested whether probiotics could boost brain health in adults 65+. The result? 🔹 ↑BDNF 🔹 ↓ perceived stress 🔹 ↑ mental flexibility Let’s break it down 👇

Just launched my new lecture on The Blind Watchmaker in Paris! A deep dive into evolution and the power of natural selection. 🍃

The microglia–gut–brain axis is emerging as a central player in neurodegeneration. New review reveals how microbial signals shape microglial states in Alzheimer’s, Parkinson’s & ALS , and where we might intervene. A new frontier in neurodegeneration? doi.org/10.1038/s41392…

7/ SC lecanemab (Leqembi IQLIK) is more than a delivery tweak, it could transform access, cost, and patient experience in Alzheimer’s care. The key questions now: ▶️How fast can health systems adapt? ▶️And how long until generic options make it widely affordable? #Alzheimers

6/ Caveats? • Still needs MRI monitoring for ARIA • Approved only for patients post-18-month IV course • High cost, complex diagnosis, and U.S.-only approval (for now) @EMA_News has approved only the IV version.

🧵1/ The @US_FDA just approved Leqembi IQLIK by @eisaiusneuro, a once-weekly subcutaneous autoinjector of lecanemab. It offers at-home convenience for patients who've completed 18 months of IV therapy. But is it just easier, or also cheaper?